Fig. 7.

The effects of Zyflamend on phosphorylation of PKCζ (at Thr410) and cellular location of PKCζ and LKB1 in HeLa cells null for LKB1, transfected with wild type (WT) LKB1 or with a catalytically dead (KD) mutant of LKB1. A Western blot of phosphorylation of PKCζ ± Zyflamend (200 μg/mL, 30 min – 3 h). B, C Western blot of pLKB1 (at Ser428) following treatment with Zyflamend, PKCζ inhibitor (5 μM, 30 min) or pretreatment with the PKCζ inhibitor plus Zyflamend (200 μg/mL, 30 min). D Western blot for PKCζ and LKB1 following subcellular fractionation (cytosol and nucleus) in HeLa cells null for LKB1, transfected with WT LKB1 or with a KD mutant of LKB1 treated with or without Zyflamend (200 μg/mL, 1 h). Representative immunoblots from 3 independent experiments are shown. Abbreviations: CON, Control; Pi, PKCζ inhibitor; Zyf, Zyflamend